Luminal B subtype: A key factor for the worse prognosis of young breast cancer patients in China

BMC Cancer

Li-Chen Tang²  Xi Jin²  Hai-Yuan Yang²  Min He²  Helena Chang¹  Zhi-Ming Shao²  Gen-Hong Di² 

[1] Department of Surgery, Revlon/UCLA Breast Canter, David Geffen School of Medicine, Los Angeles, CA, USA

[2] Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

关键词: Survival;    Characteristics;    Subtype;    Young age;    Breast cancer;   

Others  :  1161229
DOI  :  10.1186/s12885-015-1207-z

 received in 2014-12-01, accepted in 2015-03-17,  发布年份 2015

【 摘 要 】

Background

The prognoses of young breast cancer patients are poor. The purpose of this study is to evaluate the different characteristics and prognoses among different subtypes of young breast cancer patients.

Methods

The study included 1360 patients <40 years-old (y) and 3110 patients 40-50y with operable breast cancer in Shanghai Cancer Center, Fudan University. The characteristics, overall survival (OS) and disease-free survival (DFS) were compared.

Results

The median follow-up was 54.1 months. More grade III tumors and more lymph-vascular invasions (P < 0.01) were presented in <40y group when compared with 40-50y group. More patients <40y presented with Luminal B (25.3% vs. 17.5%, P < 0.01) and triple negative (16.7% vs. 13.4%, P < 0.05) breast cancer while fewer had Luminal A tumor (48.5% vs. 59.2%, P < 0.01). Younger patients with tumors of both Luminal A and Luminal B types were at increased risk for worse DFS (P = 0.03, HR = 1.69, 95% CI = 1.05-2.72; P < 0.01, HR = 3.61, 95% CI = 2.50-5.22) when compared with the older patients. Patients <40y with Luminal B tumor had a two point five fold higher risk of death compared with older counterparts (P < 0.01, HR = 2.54, 95% CI = 1.35-4.79), however, a worse overall survival rate was not observed in the younger women with Luminal A breast cancer (P > 0.05). In multivariate analysis, Luminal B subtype was also a strong predictor of disease relapse (HR = 1.09, 95% CI = 1.01 to 1.19, P < 0.01) in younger patients with Luminal subtype tumors.

Conclusion

Characteristics of breast cancer suggested a more aggressive biology in Chinese patients with breast cancer diagnosed at young age. Luminal B subtype may have a negative effect on the prognosis of young patients in China which should be validated further.

【 授权许可】

   
2015 Tang et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
• [2]Surveillance, Epidemiology, and End Results Program. SEER*Stat Database: Incidence- SEER 17 Regs Public Use, Nov. 2008 Sub (2000-2006)-Linked to County Attributes-Total US, 1969-2006 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2009. Released April 2009 based on the November 2008 submission. Available at: www.seer.cancer.gov.
• [3]Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, et al.: Breast cancer in China. Lancet Oncol 2014, 15(7):e279-89.
• [4]Han W, Kim SW, Park IA, Kang D, Kim SW, Youn YK, et al.: Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 2004, 4:82. BioMed Central Full Text
• [5]Dubsky PC, Gnant MF, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B, et al.: Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer 2002, 3(1):65-72.
• [6]Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY: Do young breast cancer patients have worse outcomes? J Surg Res 2003, 113(1):109-13.
• [7]Tang LC, Yin WJ, Di GH, Shen ZZ, Shao ZM: Unfavourable clinicopathologic features and low response rate to systemic adjuvant therapy: results with regard to poor survival in young Chinese breast cancer patients. Breast Cancer Res Treat 2010, 122(1):95-104.
• [8]Singletary SE, Connolly JL: Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 2006, 56(1):37-47. quiz 50-31
• [9]Connolly JL: Changes and problematic areas in interpretation of the AJCC Cancer Staging Manual, 6th Edition, for breast cancer. Arch Pathol Lab Med 2006, 130(3):287-91.
• [10]McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006, 100(2):229-35.
• [11]Hayes DF, Ethier S, Lippman ME: New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 2006, 100(2):237-8.
• [12]Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, et al.: Very young women (<35 years) with operable breast cancer: features of disease at presentation. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002, 13(2):273-9.
• [13]Moon EK, Park HJ, Oh CM, Jung KW, Shin HY, Park BK, et al.: Cancer incidence and survival among adolescents and young adults in Korea. PLoS One 2014, 9(5):e96088.
• [14]Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al.: Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013, 24(9):2206-23.
• [15]Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST: Stage 0 to stage III breast cancer in young women. J Am Coll Surg 2000, 190(5):523-9.
• [16]Miles RC, Gullerud RE, Lohse CM, Jakub JW, Degnim AC, Boughey JC: Local recurrence after breast-conserving surgery: multivariable analysis of risk factors and the impact of young age. Ann Surg Oncol 2012, 19(4):1153-9.
• [17]Litiere S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E, et al.: Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 2012, 13(4):412-9.
• [18]Wei XQ, Li X, Xin XJ, Tong ZS, Zhang S: Clinical features and survival analysis of very young (age < 35) breast cancer patients. Asian Pacific journal of cancer prevention : APJCP 2013, 14(10):5949-52.
• [19]Molino A, Giovannini M, Auriemma A, Fiorio E, Mercanti A, Mandara M, et al.: Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer. Crit Rev Oncol Hematol 2006, 59(3):226-33.
• [20]Tang J, Wu CC, Xie ZM, Luo RZ, Yang MT: Comparison of Clinical Features and Treatment Outcome of Breast Cancers in Young and Elderly Chinese Patients. Breast care 2011, 6(6):435-40.
• [21]R. Prati YF, D.U. Chang, M.K. Lee, S. Apple, S.A. Huryitz, H. Chang: Effect of young age on aggressive subtypes of breast cancer (BC). SSO, Abstract#2092063, March 25-28, 2015. 2015.
• [22]Lin CH, Chuang PY, Chiang CJ, Lu YS, Cheng AL, Kuo WH, et al.: Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study. Oncologist 2014, 19(6):583-91.
• [23]Horn J, Opdahl S, Engstrom MJ, Romundstad PR, Tretli S, Haugen OA, et al.: Reproductive history and the risk of molecular breast cancer subtypes in a prospective study of Norwegian women. Cancer causes control: CCC 2014, 25(7):881-9.
• [24]Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS, Amos C, Gambello M, et al.: Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Breast 2014, 23(6):770-4.
• [25]Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, et al.: BRCA-associated breast cancer in young women. J Clin Oncol Off J Am Soc Clin Oncol 1998, 16(5):1642-9.